Association of Copy Numbers of Survival Motor Neuron Gene 2 and Neuronal Apoptosis Inhibitory Protein Gene With the Natural History in a Chinese Spinal Muscular Atrophy Cohort
Restricted accessResearch articleFirst published online March, 2015
Association of Copy Numbers of Survival Motor Neuron Gene 2 and Neuronal Apoptosis Inhibitory Protein Gene With the Natural History in a Chinese Spinal Muscular Atrophy Cohort
We evaluated survival motor neuron 2 (SMN2) and neuronal apoptosis inhibitory protein (NAIP) gene copy distribution and the association of copy number with survival in 232 Chinese spinal muscular atrophy (SMA) patients. The SMN2 and NAIP copy numbers correlated positively with the median onset age (r = 0.72 and 0.377). The risk of death for patients with fewer copies of SMN2 or NAIP was much higher than for those with more copies (P < .01). The survival probabilities at 5 years were 5.1%, 90.7%, and 100% for 2, 3, and 4 SMN2 copies and 27.9%, 66.7%, and 87.2% for 0, 1, and 2 NAIP copies, respectively. Our results indicated that combined SMN1-SMN2-NAIP genotypes with fewer copies were associated with earlier onset age and poorer survival probability. Better survival status for Chinese type I SMA might due to a higher proportion of 3 SMN2 and a lower rate of zero NAIP.
OginoSLeonardDGRennertHEwensWJWilsonRB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110:301–307.
2.
ZhuSXiongFChenYJ. Molecular characterization of SMN copy number derived from carrier screening and from core families with spinal muscular atrophy in a Chinese population. Eur J Hum Genet. 2010;18:978–984.
3.
MunsatTLDaviesKE. International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2:423–428.
4.
ThomasNHDubowitzV. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord. 1994;4:497–502.
5.
ZerresKRudnik-SchönebornS. Natural history in proximal spinal muscular atrophy. Clinical analyses of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–523.
6.
ZerresKRudnik-SchönebornSForrestELusakowskaABorkowskaJHausmanowa-PetrusewiczI. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III spinal muscular atrophy): 569 patients. J Neurol Sci. 1997;146:67–72.
OskouiMLevyGGarlandCJ. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931–1936.
9.
PiepersSvan den BergLHBrugmanF. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008;255:1400–1404.
10.
Rudnik-SchönebornSBergCZerresK. Genotype–phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counseling. Clin Genet. 2009;76:168–178.
11.
GeXSBaiJLLuYJQuYJSongF. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J Child Neurol. 2012;27:471–477.
12.
KaufmannPMcDermottMPDarrasBT. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889–1897.
13.
KaufmannPMcDermottMPDarrasBT. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68:779–786.
14.
HaukeJRiesslandMLunkeS. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet. 2009;18:304–317.
15.
OpreaGEKröberSMcWhorterML. Plastin 3 Is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320:524–527.
16.
StratigopoulosGLanzanoPDengL. Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol. 2010;67:1252–1256.
FeldkötterMSchwarzerVWirthRWienkerTFWirthB. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358–368.
19.
MailmanMDHeinzJWPappAC. Molecular analyses of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20–26.
20.
CuscóIBarcelóMJRojas-GarcíaR. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol. 2006;253:21–25.
21.
QuYu-jinDuJuanLier-zhen. Subtle mutations in the SMN1 gene in Chinese patients with SMA: p.Arg288Met mutation causing SMN1 transcript exclusion of exon7. BMC Med Genet. 2012;13:86.
22.
GregorettiCOttonelloGChiarini TestaMB. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509–e1514.
23.
JedrzejowskaMMilewskiMZimowskiJ. Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease. Acta Biochim Pol. 2009;56:103–108.
24.
ArkbladETuliniusMKroksmarkAKHenricssonMDarinN. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. 2009;98:865–872.
25.
BurletPBürglenLClermontO. Large scale deletions of the 5q13 region are specific to Werdnig-Hoffmann disease. J Med Genet. 1996;33:281–283.
26.
AmaraAAdalaLBen CharfeddineI. Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients. Eur J Paediatr Neurol. 2012;16:167–174.
27.
ZheleznyakovaGYKiselevAVVakharlovskyVG. Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III. BMC Med Genet. 2011;12:96.
28.
WatihayatiMSFatemehHMariniM. Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy. Brain Dev. 2009;31:42–45.
